| Recruiting | To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psorias NCT07337434 | Syeda Sana Zaman | EARLY_Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate t NCT06011733 | UCB Biopharma SRL | Phase 3 |
| Completed | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis NCT03897075 | Sun Pharmaceutical Industries Limited | Phase 3 |
| Completed | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis NCT04286607 | Arcutis Biotherapeutics, Inc. | Phase 3 |
| Completed | Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test NCT04221906 | Boston Pharmaceuticals | Phase 1 |
| Completed | Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis NCT04211363 | Arcutis Biotherapeutics, Inc. | Phase 3 |
| Completed | Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis NCT04211389 | Arcutis Biotherapeutics, Inc. | Phase 3 |
| Completed | Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis NCT03982394 | AbbVie | — |
| Completed | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Su NCT03766685 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic P NCT03598790 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects NCT03536884 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy an NCT03410992 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic P NCT03412747 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adu NCT03370133 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chro NCT03230292 | UCB Biopharma SRL | Phase 2 |
| Completed | A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients Wi NCT03025542 | UCB Biopharma SRL | Phase 2 |
| Completed | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Pl NCT03010527 | UCB Biopharma SRL | Phase 2 |
| Completed | Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis NCT02969018 | Pfizer | Phase 2 |
| Completed | A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With M NCT02852967 | Kadmon Corporation, LLC | Phase 2 |
| Completed | Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoria NCT02905006 | UCB Biopharma S.P.R.L. | Phase 2 |
| Completed | Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects Wi NCT02690701 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis NCT02581345 | Momenta Pharmaceuticals, Inc. | Phase 3 |
| Completed | The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis NCT02570750 | Pfizer | — |
| Completed | Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque- NCT01358578 | Novartis Pharmaceuticals | Phase 3 |
| Withdrawn | Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy NCT01200264 | Duke University | Phase 2 |
| Completed | Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis NCT00805480 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris NCT00844363 | Rockefeller University | N/A |
| Completed | Chronic Plaque Psoriasis (Ps) Registry NCT00799877 | AbbVie | — |
| Completed | Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chroni NCT00770965 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Raptiva in Palm and Sole Psoriasis NCT00972543 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Unknown | Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis NCT00707070 | Universita di Verona | Phase 4 |
| Terminated | Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chron NCT00795353 | Astellas Pharma Inc | — |
| Terminated | TRUST Study: Raptiva ® in Hand & Foot Psoriasis NCT00739882 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Terminated | Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy NCT00953329 | John Murray | Phase 4 |
| Terminated | ChangE From Any Systemic psoriasiS therapY to Raptiva NCT00697593 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Completed | Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Sev NCT00574249 | Abbott | Phase 3 |
| Completed | Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque NCT00539929 | Eisai Inc. | Phase 2 |
| Completed | Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque NCT00493324 | Astellas Pharma Inc | Phase 4 |
| Completed | A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545 NCT00472758 | MedImmune LLC | Phase 1 |
| Completed | LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis NCT00705900 | NeoStrata Company, Inc. | N/A |
| Completed | A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis NCT00419666 | Galderma R&D | Phase 2 |
| Completed | Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis NCT00438360 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose NCT00512187 | Universita di Verona | Phase 4 |
| Completed | Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/ NCT00245765 | UCB Pharma | Phase 2 |
| Completed | Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients NCT00422617 | Uni-Pharma | N/A |
| Completed | Safety and Tolerability of Repeat Courses of IM Alefacept NCT00794807 | Charite University, Berlin, Germany | Phase 4 |
| Completed | A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment i NCT00673556 | Astellas Pharma Inc | Phase 3 |
| Completed | A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100 NCT00674063 | Astellas Pharma Inc | Phase 3 |
| Completed | Safety and Tolerability of Repeat Courses of IM Alefacept NCT00233662 | Biogen | Phase 3 |
| Completed | Topical Vitamin B12 in Chronic Plaque Psoriasis NCT00350116 | Ruhr University of Bochum | Phase 3 |
| Completed | Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy NCT01872546 | Poitiers University Hospital | Phase 2 |